Gregory B. Lesinski

8.2k total citations · 2 hit papers
174 papers, 5.8k citations indexed

About

Gregory B. Lesinski is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Gregory B. Lesinski has authored 174 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Oncology, 68 papers in Immunology and 58 papers in Molecular Biology. Recurrent topics in Gregory B. Lesinski's work include Cancer Immunotherapy and Biomarkers (41 papers), Pancreatic and Hepatic Oncology Research (30 papers) and Cytokine Signaling Pathways and Interactions (24 papers). Gregory B. Lesinski is often cited by papers focused on Cancer Immunotherapy and Biomarkers (41 papers), Pancreatic and Hepatic Oncology Research (30 papers) and Cytokine Signaling Pathways and Interactions (24 papers). Gregory B. Lesinski collaborates with scholars based in United States, China and Israel. Gregory B. Lesinski's co-authors include Gregory Young, Thomas A. Mace, William E. Carson, Bassel F. El‐Rayes, Tanios Bekaii‐Saab, Mark Bloomston, M.A. Julie Westerink, Christina Wu, Mehmet Akce and James R. Fuchs and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Gregory B. Lesinski

166 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer

2016 401 citations Thomas A. Mace, Reena Shakya et al. profile →
Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms

2019 263 citations Gregory B. Lesinski, Bassel F. El‐Rayes et al. profile →

Peers

Countries citing papers authored by Gregory B. Lesinski

Since Specialization

Citations

This map shows the geographic impact of Gregory B. Lesinski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory B. Lesinski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory B. Lesinski more than expected).

Fields of papers citing papers by Gregory B. Lesinski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory B. Lesinski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory B. Lesinski. The network helps show where Gregory B. Lesinski may publish in the future.

Co-authorship network of co-authors of Gregory B. Lesinski

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory B. Lesinski. A scholar is included among the top collaborators of Gregory B. Lesinski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory B. Lesinski. Gregory B. Lesinski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Constructing the cure: engineering the next wave of antibody and cellular immune therapies 2025 ·Journal for ImmunoTherapy of Cancer ·Stefanie R. Bailey, Eric Bartee, Kyle G. Daniels, Christopher R. Heery, Pravin T. P. Kaumaya, Gregory B. Lesinski, Timothy B. Lowinger, Michelle H. Nelson, Mark P. Rubinstein, (unknown), Chrystal M. Paulos, Avery D. Posey	0
2	A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer. 2024 ·Journal of Clinical Oncology ·Thatcher Heumann, Mark Yarchoan, (unknown), Jiayun Lu, Daneng Li, Paul R. Kunk, Renuka Iyer, Farshid Dayyani, Lionel Aurelien Kankeu Fonkoua, (unknown), Olumide B. Gbolahan, Milind Javle, S. Lindsey Davis, Vaia Florou, James R. Wright, Elad Sharon, Hao Wang, Gregory B. Lesinski, Nilofer S. Azad	3
3	VPAC2 Receptor Signaling Promotes Growth and Immunosuppression in Pancreatic Cancer 2024 ·Cancer Research ·(unknown), (unknown), Hanwen Zhang, (unknown), (unknown), (unknown), (unknown), Yuan Liu, Sruthi Ravindranathan, Gregory B. Lesinski, Edmund K. Waller	4
4	Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer 2022 ·Clinical Cancer Research ·(unknown), Mark Yarchoan, Subir Goyal, Yuan Liu, Elad Sharon, (unknown), Brian M. Olson, Chrystal M. Paulos, Bassel F. El‐Rayes, Shishir K. Maithel, Nilofer S. Azad, Gregory B. Lesinski	10
5	The phase 1/2 trial of indomethacin in chronic pancreatitis (The PAIR trial): Protocol for a parallel multi-center randomized controlled trial 2022 ·Pancreatology ·Samuel Han, Darwin L. Conwell, Liang Li, (unknown), Phil A. Hart, Zobeida Cruz‐Monserrate, Wenrui Hao, Gregory B. Lesinski, Thomas A. Mace, Tonya M. Palermo, Jami L. Saloman, Dhiraj Yadav, Santhi Swaroop Vege, Mark Topazian	7
6	Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist Therapy 2021 ·Cancer Immunology Research ·Lauren Dennison, (unknown), Aditya Mohan, James M. Leatherman, Kayla Cruz, Skylar Woolman, Nilofer S. Azad, Gregory B. Lesinski, Elizabeth M. Jaffee, Mark Yarchoan	17
7	Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer 2020 ·Molecular Cancer Therapeutics ·(unknown), (unknown), Mohammad Y. Zaidi, (unknown), Brian M. Olson, (unknown), Matthew R. Farren, Ganji Purnachandra Nagaraju, Chao Zhang, Zhengjia Chen, Juan M. Sarmiento, Rafi Ahmed, Shishir K. Maithel, Bassel F. El‐Rayes, Gregory B. Lesinski	39
8	The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors 2017 ·Molecular Cancer Therapeutics ·Matthew R. Farren, (unknown), Reena Shakya, (unknown), Gregory Young, Kari Kendra, Yosef Landesman, Sivan Elloul, Marsha Crochiere, Boris Klebanov, Trinayan Kashyap, Christin E. Burd, Gregory B. Lesinski	23
9	Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment 2017 ·Cancer Research ·(unknown), Agnieszka Świdnicka‐Siergiejko, (unknown), Myrriah Chavez-Tomar, Gregory B. Lesinski, Tanios Bekaii‐Saab, Matthew R. Farren, Thomas A. Mace, Carl Schmidt, Yan Liu, Defeng Deng, Rosa F. Hwang, Liran Zhou, Todd T. Moore, Deyali Chatterjee, Huamin Wang, Xiaohong Leng, Ralph B. Arlinghaus, Craig D. Logsdon, Zobeida Cruz‐Monserrate	114
10	Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities 2016 ·Molecular Cancer Therapeutics ·Erin E. Talbert, Jennifer Yang, Thomas A. Mace, Matthew R. Farren, Alton B. Farris, Gregory Young, (unknown), (unknown), Cynthia Timmers, Priyani Rajasekera, (unknown), Mark Bloomston, Tanios Bekaii‐Saab, Denis C. Guttridge, Gregory B. Lesinski	29
11	Isoflavone Pharmacokinetics and Metabolism after Consumption of a Standardized Soy and Soy–Almond Bread in Men with Asymptomatic Prostate Cancer 2015 ·Cancer Prevention Research ·Jennifer Ahn‐Jarvis, Steven K. Clinton, Elizabeth M. Grainger, Kenneth M. Riedl, Steven J. Schwartz, Mei‐Ling Ting Lee, Raul Cruz‐Cano, Gregory Young, Gregory B. Lesinski, Yael Vodovotz	29
12	Consumption of Soy Isoflavone Enriched Bread in Men with Prostate Cancer Is Associated with Reduced Proinflammatory Cytokines and Immunosuppressive Cells 2015 ·Cancer Prevention Research ·Gregory B. Lesinski, Patrick K. Reville, Thomas A. Mace, Gregory Young, Jennifer Ahn‐Jarvis, Jennifer M. Thomas‐Ahner, Yael Vodovotz, Zeenath Ameen, Elizabeth M. Grainger, Kenneth M. Riedl, Steven D. Schwartz, Steven K. Clinton	70
13	Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer 2015 ·Clinical Cancer Research ·Matthew R. Farren, Thomas A. Mace, Susan Geyer, Sameh Mikhail, Christina Wu, Kristen K. Ciombor, Sanaa Tahiri, Daniel H. Ahn, Anne M. Noonan, Miguel A. Villalona‐Calero, Tanios Bekaii‐Saab, Gregory B. Lesinski	69
14	A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma 2014 ·Clinical Cancer Research ·Douglas W. Sborov, Gerard J. Nuovo, Andrew Stiff, Thomas A. Mace, Gregory B. Lesinski, Don M. Benson, Yvonne A. Efebera, Ashley Rosko, Flavia Pichiorri, Michael R. Grever, Craig C. Hofmeister	71
15	Pancreatic Cancer-Associated Stellate Cells Promote Differentiation of Myeloid-Derived Suppressor Cells in a STAT3-Dependent Manner 2013 ·Cancer Research ·Thomas A. Mace, Zeenath Ameen, Amy Collins, Sylwia E. Wojcik, Markus Mair, Gregory Young, James R. Fuchs, Timothy D. Eubank, Wendy L. Frankel, Tanios Bekaii‐Saab, Mark Bloomston, Gregory B. Lesinski	344
16	Myeloid-Derived Suppressor Cell Inhibition of the IFN Response in Tumor-Bearing Mice 2011 ·Cancer Research ·Bethany L. Mundy-Bosse, Gregory B. Lesinski, Alena Cristina Jaime‐Ramirez, Kristen Benninger, Mahmood Khan, Periannan Kuppusamy, Kristan Guenterberg, Sri Vidya Kondadasula, Abhik Ray Chaudhury, Krista M. D. La Perle, (unknown), Gregory Young, Denis C. Guttridge, William E. Carson	149
17	IFN-α and Bortezomib Overcome Bcl-2 and Mcl-1 Overexpression in Melanoma Cells by Stimulating the Extrinsic Pathway of Apoptosis 2008 ·Cancer Research ·Gregory B. Lesinski, (unknown), Kristan Guenterberg, (unknown), Michael R. Go, Nisha Shah, (unknown), (unknown), Erinn M. Hade, Gregory Young, Abhik Ray Chaudhury, Katherine J. Ladner, Denis C. Guttridge, Page Bouchard, William E. Carson	44
18	Gene Expression Profiling Reveals Similarities between the In vitro and In vivo Responses of Immune Effector Cells to IFN-α 2008 ·Clinical Cancer Research ·Jason M. Zimmerer, Gregory B. Lesinski, Amy S. Ruppert, Michael D. Radmacher, (unknown), Kari Kendra, Michael J. Walker, William E. Carson	27
19	Melanoma Cells Exhibit Variable Signal Transducer and Activator of Transcription 1 Phosphorylation and a Reduced Response to IFN-α Compared with Immune Effector Cells 2007 ·Clinical Cancer Research ·Gregory B. Lesinski, John C. Trefry, (unknown), Sri Vidya Kondadasula, (unknown), Jason M. Zimmerer, Abhik Ray Chaudhury, Lianbo Yu, Xiaoli Zhang, (unknown), Michael J. Walker, William E. Carson	30
20	The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse 2003 ·Journal of Clinical Investigation ·Gregory B. Lesinski, Mirela Anghelina, Jason M. Zimmerer, (unknown), Brian D. Badgwell, Robin Parihar, Yan Hu, Brian Becknell, Gerard Abood, Abhik Ray Chaudhury, Cynthia M. Magro, Joan E. Durbin, William E. Carson	97

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact